Skip to main content
. 2022 Feb 16;13:812317. doi: 10.3389/fimmu.2022.812317

Figure 4.

Figure 4

(A, B) Abundance (A) or expression levels (B) of BAFF-R and/or CXCR5 on total or BAFF-R+ B cells. (C) Expression of BAFF-R and CXCR5 on total B cells. (D) Correlation of BAFF-R+ and CXCR5+ B cells in CIS/MS patients and controls. (E) Correlation of expression levels of BAFF-R and CXCR5 on BAFF-R+ and CXCR5+ B cells in CIS/MS patients and controls. (F) Correlation of BAFF-R expression on BAFF-R+ B cells and serum BAFF levels. (G, H) BAFF-R expression on BAFF-R+ B cells at study recruitment and at 2 months (2M) and 3 months (3M) follow-up, displayed as raw data (G) or mean ± SD change from baseline (H). Data in (A, B, D, E) are displayed for each participant, together with box/whiskers display for median and range where relevant (n CIS/MS = 28, n Controls = 17). Data in (C) is displayed from a representative individual and in (F) from a subset of individuals (n CIS/MS = 6). In (G, H), data is displayed for (n Baseline = 15, n 2M = 15, n 3M = 14). Correlations are visualized using a linear fit and 95% CI. Significance of difference between patient groups versus controls was calculated using Mann-Whitney non-parametric test on the raw data, correlation was calculated using Spearman non-parametric test and displayed as p<0.001, ***; p<0.01, **; p<0.05, *.